TWI228127B - Substituted imidazoles as histamine H3 or dual histamine H1 and H3 antagonists - Google Patents

Substituted imidazoles as histamine H3 or dual histamine H1 and H3 antagonists Download PDF

Info

Publication number
TWI228127B
TWI228127B TW090123022A TW90123022A TWI228127B TW I228127 B TWI228127 B TW I228127B TW 090123022 A TW090123022 A TW 090123022A TW 90123022 A TW90123022 A TW 90123022A TW I228127 B TWI228127 B TW I228127B
Authority
TW
Taiwan
Prior art keywords
compound
patent application
cns
scope
national standard
Prior art date
Application number
TW090123022A
Other languages
English (en)
Chinese (zh)
Inventor
Neng-Yang Shih
Daniel M Solomon
John J Piwinski
Robert G Aslanian
Stuart B Rosenblum
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TWI228127B publication Critical patent/TWI228127B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW090123022A 2000-09-20 2001-09-19 Substituted imidazoles as histamine H3 or dual histamine H1 and H3 antagonists TWI228127B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23403900P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
TWI228127B true TWI228127B (en) 2005-02-21

Family

ID=22879625

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090123022A TWI228127B (en) 2000-09-20 2001-09-19 Substituted imidazoles as histamine H3 or dual histamine H1 and H3 antagonists

Country Status (14)

Country Link
US (1) US6762186B2 (https=)
EP (1) EP1318996B1 (https=)
JP (1) JP2004514709A (https=)
CN (1) CN1461304A (https=)
AR (1) AR032894A1 (https=)
AT (1) ATE283853T1 (https=)
AU (1) AU2002241459A1 (https=)
CA (1) CA2422729A1 (https=)
DE (1) DE60107586T2 (https=)
ES (1) ES2233708T3 (https=)
HK (1) HK1052182B (https=)
MX (1) MXPA03002446A (https=)
TW (1) TWI228127B (https=)
WO (1) WO2002044141A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268117A1 (en) * 2002-09-18 2004-04-08 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
US8063650B2 (en) 2002-11-27 2011-11-22 Rambus Inc. Testing fuse configurations in semiconductor devices
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
BRPI0413013A (pt) 2003-07-28 2006-10-03 Smithkline Beecham Corp composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
JP2009504637A (ja) * 2005-08-08 2009-02-05 アストラゼネカ・アクチエボラーグ 治療薬
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
KR20090097194A (ko) 2006-12-22 2009-09-15 아벡사 리미티드 바이사이클 피리미디논 및 그 용도
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
EP0437645B1 (de) * 1990-01-15 1995-03-29 HEUMANN PHARMA GMBH & CO Imidazolylpropylguanidinderivat, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel
ES2058651T3 (es) 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
FR2665160A1 (fr) * 1990-07-26 1992-01-31 Esteve Labor Dr Nouveaux derives de 1-diphenylmethylpiperazine, leur preparation et leur application en tant que medicaments.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HU213104B (en) * 1992-06-17 1997-02-28 Richter Gedeon Vegyeszet Process for producing 4-methyl-2-imidazolinone derivatives and pharmaceutical compositions containing them
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
WO1998058646A1 (en) 1997-06-24 1998-12-30 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists

Also Published As

Publication number Publication date
AU2002241459A1 (en) 2002-06-11
DE60107586D1 (de) 2005-01-05
ATE283853T1 (de) 2004-12-15
ES2233708T3 (es) 2005-06-16
US6762186B2 (en) 2004-07-13
HK1052182A1 (en) 2003-09-05
AR032894A1 (es) 2003-12-03
MXPA03002446A (es) 2003-06-19
EP1318996B1 (en) 2004-12-01
HK1052182B (en) 2005-04-01
CN1461304A (zh) 2003-12-10
EP1318996A2 (en) 2003-06-18
US20020082278A1 (en) 2002-06-27
JP2004514709A (ja) 2004-05-20
WO2002044141A3 (en) 2002-11-07
WO2002044141A2 (en) 2002-06-06
CA2422729A1 (en) 2002-06-06
DE60107586T2 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
US7666867B2 (en) Heteroindanes: a new class of potent cannabimimetic ligands
JP5431316B2 (ja) Ｃｃｒ２受容体アンタゴニストとしてのイミダゾール誘導体
CN103974950B (zh) 作为ccr(4)拮抗剂的取代的苯并咪唑类和苯并吡唑类
CA3215564A1 (en) Methods and compounds for restoring mutant p53 function
TW200403223A (en) Novel compounds
TWI228127B (en) Substituted imidazoles as histamine H3 or dual histamine H1 and H3 antagonists
JP2002536291A (ja) ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
TW200940524A (en) Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
CN101384549A (zh) 吡咯衍生物或其盐
TW589303B (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
JP2006151810A (ja) ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US6518287B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6528522B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
EP1735302B1 (en) 4-amino-piperidine derivatives as monoamine uptake inhibitors
CN100364990C (zh) 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees